Skip to main content
SpringerLink
Log in

Nocebo in Headache Treatment

  • Chapter
  • First Online:
Placebos and Nocebos in Headaches

Part of the book series: Headache ((HEAD))

  • 550 Accesses

Abstract

Nocebo refers to adverse events (AEs) related to negative expectations that medical treatment will likely harm instead of heal and affects significantly adherence and treatment outcome. It varies considerably among neurological conditions but can be assessed in placebo-controlled clinical trials (RCTs) by investigating the AEs observed in patients treated with placebo. In clinical practice nocebo can be predicted by applying the Q-No questionnaire. Clinically relevant outcomes for nocebo in RCTs include the percentage of patients treated with placebo who experienced any AE (nocebo AE) and the percentage of patients who discontinued treatment due to AEs although treated with placebo (nocebo withdrawal). Meta-analyses of RCTs for migraine prevention estimated that nocebo AE and withdrawal rise up to 42.78% (95% CI 34.73–51.36%) and 4.75% (95% CI 3.28–6.45%) of placebo-treated patients. In studies for symptomatic treatment for migraine, the nocebo AE and withdrawal frequencies were 18.45% (95% CI 14.90–22.23%) and 0.33% (95% CI 0.19–0.53%), respectively. In trials for prevention of tension-type headache (TTH), nocebo and dropout frequencies were 23.99% (95% CI 4.61–52.20%) and 5.44% (95% CI 1.32–12.12%). For symptomatic treatment of cluster headache, the nocebo AE frequency was 18.67% (95% CI 10.65–28.33%; insufficient data were gathered to calculate the nocebo withdrawal). In clinical practice nocebo can be predicted by using the Q-No questionnaire, a four-item (rating range 4–20) self-fulfilled questionnaire. Using a cutoff at score 15, the Q-No predicts nocebo with 71.7% specificity, 67.5% sensitivity, and 42.5% positive predictive value. Almost 57% of headache sufferers score more than 15 indicating potential nocebo behaviors that contributed significantly in their therapy choices, as well as in treatment adherence. These data indicate that nocebo plays a severe role in headache therapeutics requiring major attention and appropriate management, although it remains largely unknown and underappreciated.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 99.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Amanzio M, Corazzini LL, Vase L, Benedetti F. A systematic review of adverse events in placebo groups of anti-migraine clinical trials. Pain. 2009;146(3):261–9.

    Article  CAS  PubMed  Google Scholar 

  2. Bartels DJP, van Laarhoven AIM, Stroo M, Hijne K, Peerdeman KJ, Donders ART, van de Kerkhof PCM, Evers AWM. Minimizing nocebo effects by conditioning with verbal suggestion: a randomized clinical trial in healthy humans. PLoS One. 2017;12(9):e0182959.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Blassini M, Corsi N, Klinger R, Colloca L. Nocebo and pain: an overview of the psychoneurobiological mechanisms. Pain Rep. 2017;2(2). pii: e585.

    Google Scholar 

  4. Benedetti F, Amanzio M. The placebo response: how words and rituals change the patient’s brain. Patient Educ Couns. 2011;84(3):413–9.

    Article  PubMed  Google Scholar 

  5. Benedetti F, Lanotte M, Lopiano L, Colloca L. When word are painful: unraveling the mechanisms of the nocebo effect. Neuroscience. 2007;147:260–71.

    Article  CAS  PubMed  Google Scholar 

  6. Bingel U. Avoiding nocebo effects to optimize treatment outcome. JAMA. 2014;312:693–4.

    Article  CAS  PubMed  Google Scholar 

  7. Colloca L. Placebo, nocebo, and learning mechanisms. Handb Exp Pharmacol. 2014;225:17–35.

    Article  PubMed  Google Scholar 

  8. Colloca L, Grillon C. Understanding placebo and nocebo responses for pain management. Curr Pain Headache Rep. 2014;18:419.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Colloca L, Finniss D. Nocebo effects, patient-clinician communication, and therapeutic outcomes. JAMA. 2012;307:567–8.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Dodd S, Schacht A, Kelin K, Dueñas H, Reed VA, Williams LJ, Quirk FH, Malhi GS, Berk M. Nocebo effects in the treatment of major depression: results from an individual study participant-level meta-analysis of the placebo arm of duloxetine clinical trials. J Clin Psychiatry. 2015;76(6):702–11.

    Article  PubMed  Google Scholar 

  11. GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390:1211–59.

    Article  Google Scholar 

  12. Greville-Harris M, Dieppe P. Bad is more powerful than good: the nocebo response in medical consultations. Am J Med. 2015;128:126–9.

    Article  PubMed  Google Scholar 

  13. Gracia-Naya M, Santos-Lasaosa S, Ríos-Gómez C, Sánchez-Valiente S, García-Gomara MJ, Latorre-Jiménez AM, Artal-Roy J, Mauri-Llerda JA. Predisposing factors affecting drop-out rates in preventive treatment in a series of patients with migraine. Rev Neurol. 2011;53:201–8.

    PubMed  Google Scholar 

  14. Gupta A, Thompson D, Whitehouse A, Collier T, Dahlof B, Poulter N, Collins R, Sever P, ASCOT Investigators. Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA): a randomized double blind placebo-controlled trial and its non-randomized non-blind extension phase. Lancet. 2017;389(10088):2473–81.

    Article  CAS  PubMed  Google Scholar 

  15. Hepp Z, Dodick DW, Varon SF, Gillard P, Hansen RN, Devine EB. Adherence to oral migraine-preventive medications among patients with chronic migraine. Cephalalgia. 2015;35:478–88.

    Article  PubMed  Google Scholar 

  16. Hepp Z, Bloudek LM, Varon SF. Systematic review of migraine prophylaxis adherence and persistence. J Manag Care Pharm. 2014;20:22–33.

    PubMed  Google Scholar 

  17. Klosterhalfen S, Kellermann S, Braun S, Kowalski A, Schrauth M, Zipfel S, Enck P. Gender and the nocebo response following conditioning and expectancy. J Psychosom Res. 2009;66(4):323–8.

    Article  PubMed  Google Scholar 

  18. Loder E, Goldstein R, Biondi D. Placebo effects in oral triptan trials: the scientific and ethical rationale for continued use of placebo controls. Cephalalgia. 2005;25:124–31.

    Article  CAS  PubMed  Google Scholar 

  19. McCormack JP, Allan GM, Virani AS. Is bigger better? An argument for very low starting doses. CMAJ. 2011;183:65–9.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Meister R, Jansen A, Härter M, Nestoriuc Y, Kriston L. Placebo and nocebo reactions in randomized trials of pharmacological treatments for persistent depressive disorder. A meta-regression analysis. J Affect Disord. 2017;215:288–98.

    Article  CAS  PubMed  Google Scholar 

  21. Mitsikostas DD. Nocebo in headaches: implications for clinical practice and trial design. Curr Neurol Neurosci Rep. 2012;12:132–7.

    Article  PubMed  Google Scholar 

  22. Mitsikostas DD. Nocebo in headache. Curr Opin Neurol. 2016;29(3):331–6.

    Article  PubMed  Google Scholar 

  23. Mitsikostas DD, Deligianni CI. Q-No: a questionnaire to predict nocebo in & outpatients seeking neurological consultation. Neurol Sci. 2015;36:379–81.

    Article  PubMed  Google Scholar 

  24. Mitsikostas DD, Belesioti I, Arvaniti C, Mitropoulou E, Deligianni C, Kasioti E, Constantinidis T, Dermitzakis M, Vikelis M. Hellenic Headache Society. Patients’ preferences for headache acute and preventive treatment. J Headache Pain. 2017;18(1):102.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Mitsikostas DD, Chalarakis NG, Mantonakis LI, Delicha EM, Sfikakis PP. Nocebo in fibromyalgia: meta-analysis of placebo-controlled clinical trials and implications for practice. Eur J Neurol. 2012;19(5):672–80.

    Article  CAS  PubMed  Google Scholar 

  26. Mitsikostas DD, Mantonakis LI, Chalarakis NG. Nocebo is the enemy, not placebo. A meta-analysis of reported side effects after placebo treatment in headaches. Cephalalgia. 2011;31:550–61.

    Article  PubMed  Google Scholar 

  27. Mitsikostas DD, Mantonakis L, Chalarakis N. Nocebo in clinical trials for depression: a meta-analysis. Psychiatry Res. 2014;215(1):82–6.

    Article  PubMed  Google Scholar 

  28. Petersen GL, Finnerup NB, Colloca L, Amanzio M, Price DD, Jensen TS, Vase L. The magnitude of nocebo effects in pain: a meta-analysis. Pain. 2014;155(8):1426–34.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Papadopoulos D, Mitsikostas DD. A meta-analytic approach to estimating nocebo effects in neuropathic pain trials. J Neurol. 2012;259:436–47.

    Article  PubMed  Google Scholar 

  30. Papadopoulos D, Mitsikostas DD. Nocebo effects in multiple sclerosis trials: a meta-analysis. Mult Scler. 2010;16:816–28.

    Article  CAS  PubMed  Google Scholar 

  31. Reuter U, Sanchez del Rio M, Carpay JA, Boes CJ, Silberstein SD. GSK headache masters program: placebo adverse events in headache trials: headache as an adverse event of placebo. Cephalalgia. 2003;23:496–503.

    Article  CAS  PubMed  Google Scholar 

  32. Rozen TD, Fishman RS. Cluster headache in the United States of America: demographics, clinical characteristics, triggers, suicidality, and personal burden. Headache. 2012;52:99–113.

    Article  PubMed  Google Scholar 

  33. Silva MA, Duarte GS, Camara R, Rodrigues FB, Fernandes RM, Abreu D, Mestre T, Costa J, Trenkwalder C, Ferreira JJ. Placebo and nocebo responses in restless legs syndrome: a systematic review and meta-analysis. Neurology. 2017;88(23):2216–24.

    Article  PubMed  Google Scholar 

  34. Silvestri A, Galetta P, Cerquetani E, Marazzi G, Patrizi R, Fini M, Rosano GM. Report of erectile dysfunction after therapy with beta-blockers is related to patient knowledge of side effects and is reversed by placebo. Eur Heart J. 2003;24(21):1928–32.

    Article  CAS  PubMed  Google Scholar 

  35. Stathis P, Smpiliris M, Konitsiotis S, Mitsikostas DD. Nocebo as a potential confounding factor in clinical trials for Parkinson’s disease treatment: a meta-analysis. Eur J Neurol. 2013;20:527–33.

    Article  CAS  PubMed  Google Scholar 

  36. Steiner TJ, Stovner LJ, Katsarava Z, Lainez JM, Lampl C, Lantéri-Minet M, Rastenyte D, Ruiz de la Torre E, Tassorelli C, Barré J, Andrée C. The impact of headache in Europe: principal results of the Eurolight project. J Headache Pain. 2014;15:31.

    Article  PubMed  PubMed Central  Google Scholar 

  37. Tinnermann A, Geuter S, Sprenger C, Finsterbusch J, Büchel C. Interactions between brain and spinal cord mediate value effects in nocebo hyperalgesia. Science. 2017;358(6359):105–8.

    Article  CAS  PubMed  Google Scholar 

  38. Webster RK, Weinman J, Rubin GJ. A systematic review of factors that contribute to nocebo effects. Health Psychol. 2016;35(12):1334–55.

    Article  PubMed  Google Scholar 

  39. Zaccara G, Giovannelli F, Giorgi FS, Franco V, Gasparini S. Analysis of nocebo effects of antiepileptic drugs across different conditions. J Neurol. 2016;263(7):1274–9.

    Article  CAS  PubMed  Google Scholar 

  40. Zis P, Shafiq F, Mitsikostas DD. Nocebo effect in refractory partial epilepsy during pre-surgical monitoring: systematic review and meta-analysis of placebo-controlled clinical trials. Seizure. 2017;45:95–9.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. 1st Neurology Department, Aeginition Hospital, National and Kapodistrian University of Athens, Athens, Greece

    Christina Deligianni & Dimos D. Mitsikostas

Authors
  1. Christina Deligianni
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dimos D. Mitsikostas
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Dimos D. Mitsikostas .

Editor information

Editors and Affiliations

  1. Neurology Department, Aeginition Hospital, National and Kapodistrian University of Athens, Athens, Greece

    Dimos D. Mitsikostas

  2. Neuroscience Department, University of Turin Medical School, Torino, Italy

    Fabrizio Benedetti

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Deligianni, C., Mitsikostas, D.D. (2019). Nocebo in Headache Treatment. In: Mitsikostas, D., Benedetti, F. (eds) Placebos and Nocebos in Headaches. Headache. Springer, Cham. https://doi.org/10.1007/978-3-030-02976-0_7

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-02976-0_7

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-02975-3

  • Online ISBN: 978-3-030-02976-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation